Behind Cuba's successful pandemic responseBehind Cuba's successful pandemic response

by Talha Burki, The Lancet Infectious Disease

Cuba’s long-standing commitment to health has led to a successful COVID-19 pandemic response, but it is threatened by financial and supplier issues. Talha Burki reports.As The Lancet Infectious Diseases went to press, Cuba was due to launch a phase 3 trial of its subunit conjugate vaccine against COVID-19. Soberana-2 is one of four candidate COVID-19 vaccines in development in Cuba. It is produced by the Finlay Institute in Havana. On the basis of as-yet-unpublished results from early-stage clinical trials, Vicente Verez-Bencomo, director-general of the Finlay Institute, expects the vaccine to show an efficacy in the region of 80–95%. “We are very optimistic”, he said. If everything goes according to plan, Cuba could start a mass vaccination programme for its 11¡2 million citizens sometime in the summer.

Avatar

By US-Cuba Normalization Committee

Organizing Committee, International and Nationwide Conference for the Normalization of US-Cuba Relations.

Comments are closed.